Baisheng Biotech Secures Tens of Millions RMB in Pre-A Financing Led by Zhongda Venture Capital and Yanghe Investment

Recently, Baisheng (Guangzhou) Biological Products Co., Ltd. (hereinafter referred to as “Baisheng Biologics”) announced the completion of its RMB 10 million Pre-A round strategic financing, jointly invested by Zhongda Venture Capital and Yanghe Investment. The proceeds from this round will be primarily used to advance market expansion for pathological diagnostic products and further research and development of its product pipeline.

Baisheng Bio, established in December 2018, is an innovative biotechnology enterprise located within the Guangdong Medical Valley Nansha Industrial Park. The company specializes in providing products and services across the entire industrial chain of tumor pathological diagnosis, with a comprehensive product portfolio spanning histomorphology, immunohistochemistry, and molecular diagnostics. Its core team comprises highly qualified pathology professionals, including postdoctoral fellows, PhDs, master’s degree holders, and overseas-educated experts, all possessing 5–10 years of experience in the pathology industry, with the majority hailing from renowned pharmaceutical and pathological diagnostic companies.

Since its establishment, Baisheng Biological has successfully launched a range of flagship products through continuous investment and independent research and development, including high-throughput fully automated immunohistochemistry stainers, high-definition HE drip stainers, special staining instruments, polymer-labeled secondary antibodies, and monoclonal cell lines. Baisheng Biological strives to achieve full industry chain control encompassing product R&D, manufacturing, sales, and after-sales service, providing first-class products and services to the industry. Furthermore, the company actively promotes the adoption of advanced pathological diagnostic technologies and the innovation of domestically produced products, basing itself in China while serving the global market.

Dr. Tan Ruizheng, founder of Baisheng (Guangzhou) Biological Products Co., Ltd., expressed his sincere gratitude for the continued support and recognition from institutions such as Zhongda Venture Capital Co., Ltd. and Yanghe Investment. Currently, Baisheng Biological has obtained registration certificates for 389 pathology-related products. The company’s instruments and biological reagents have been deployed and are in use at dozens of hospitals across China, with customers reporting highly satisfactory performance. Notably, through continuous innovation, the company has launched the industry’s only all-in-one system integrating high-throughput immunohistochemistry, high-definition HE drip staining, special staining, and fluorescence in situ hybridization (FISH). This four-in-one platform provides a one-stop solution for pathology departments, significantly enhancing their operational efficiency and economic benefits. Baisheng Biological will continue to increase its investment in R&D and operational promotion to deliver returns to its investors.

For this round of investment,Zhongda Venture Capital President Zheng GuihuiIt was stated that “pathological diagnosis is the gold standard for clinical diagnosis and holds significant importance in tumor diagnosis. Currently, China has a large population of cancer patients, with rising incidence and mortality rates. However, precision testing methods for tumors still lack standardization in many areas, leaving numerous clinical needs unmet. Through technological innovation, the founding team of Baisheng (Guangzhou) Biological Products Co., Ltd. has gradually built a comprehensive portfolio of pathology products and continuously enhanced its operational management capabilities. We believe that Baisheng Bio can become an innovator and leader in the field of comprehensive pathological diagnostics. Zhongda Venture Capital Co., Ltd. will fully leverage its rich industrial ecosystem resources to continuously support the future development of Baisheng Bio.”

”

Regarding the investment in Baisheng Biological,Ms. Tan Fei, Investment Director of Yanghe InvestmentHe stated, “Amid the broader trend of price reductions driven by centralized procurement, the reimbursement rates for multiple clinical pathology testing items have been adjusted upward. This reflects the state’s supportive stance toward pathology testing, suggesting that the sector is poised for rapid growth over the next decade. With the founding team of Baisheng Biological having deeply cultivated the field of pathological immunohistochemistry for many years, we are confident that Baisheng Biological will stand out in the pathology testing landscape.”

Zhongda Venture Capital, established in 2011, is an emerging industry investment institution dedicated to fully leveraging the advantages and resources of Chinese universities in technological innovation, industrial research, and talent development. It rationally mobilizes and allocates social capital to support the commercialization of scientific and technological achievements. Adhering to the investment philosophy of “trend-based investing, industrial investing, ecosystem building, and aggregated innovation,” Zhongda Venture Capital focuses on fund management, equity investment, IPOs, and mergers and acquisitions, with key investments in emerging sectors such as biopharmaceuticals, new materials, and advanced manufacturing. Through continuous exploration and development, the firm has formed a development model integrating “industrial clusters + industrial finance + innovation ecosystem.” By establishing three major industrial clusters—Guangdong Medical Valley, Guangdong Materials Valley, and Zhongda Innovation Valley—it has built unique advantages in biopharmaceuticals, new materials, and advanced manufacturing. Furthermore, by hosting branded events such as Open Days, industry seminars, and high-level forums, it gathers innovative enterprises, cutting-edge technologies, and professional talent, thereby extending its reach into emerging industry trends and continuously identifying and investing in innovative companies with significant growth potential.

Yanghe Investment, founded in 2013, is a China-based industrial investment firm dedicated to niche sectors within the healthcare industry. It focuses primarily on medical technologies, innovative medical devices, and healthcare services, with its portfolio concentrated in early-to-mid-stage ventures. Committed to long-term value creation, the firm identifies investment opportunities through in-depth research of specialized market segments and empowers its portfolio companies, achieving its own growth by fostering the success of its investments.